Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
efalizumab
Serono Europe Limited
L04AA21
efalizumab
Immunosuppressants
Psoriasis
Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (see section 5.1 - Clinical Efficacy).
Revision: 8
Withdrawn
2004-09-20
Medicinal product no longer authorised 23 B. PACKAGE LEAFLET Medicinal product no longer authorised 24 PACKAGE LEAFLET: INFORMATION FOR THE USER RAPTIVA 100 MG/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION EFALIZUMAB READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions,ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Raptiva is and what it is used for 2. Before you use Raptiva 3. How to use Raptiva 4. Possible side effects 5 How to store Raptiva 6. Further information 1. WHAT RAPTIVA IS AND WHAT IT IS USED FOR Raptiva is a systemic psoriasis medicine. Systemic therapies are medicines taken orally or administered by injection and thus will be present in and affect the whole body. Raptiva is a medicine containing efalizumab, made by means of biotechnology. It is produced by genetically engineered mammalian cells. Efalizumab is a monoclonal antibody. Monoclonal antibodies are proteins that recognise and bind to other specific proteins of the human body. Efalizumab reduces inflammation of the psoriatic lesions which results in improvement of the affected areas of the skin. THERAPEUTIC INDICATIONS Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA. This restriction of the indication of Raptiva is based on the present efficacy data and limited long-term experience with Raptiva. 2. BEFORE YOU USE RAPTIVA Ask your doctor or pharmacist for advice before taking any medicine. DO NOT USE RAPTIVA: - If you are allergic (hypersensitive) to efalizumab or a Przeczytaj cały dokument
Medicinal product no longer authorised 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Raptiva 100 mg/ml powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _ _ Each vial contains a retrievable amount of 125 mg of efalizumab. Reconstitution with the solvent yields a solution containing efalizumab at 100 mg/ml. Efalizumab is a recombinant humanized monoclonal antibody produced in genetically engineered Chinese Hamster Ovary (CHO) cells. Efalizumab is an IgG1 kappa immunoglobulin, containing human constant region sequences and murine light- and heavy-chain complementary determining region sequences. Excipients: 2.5 mg polysorbate 20, 3.55 mg histidine, 5.70 mg histidine hydrochloride monohydrate, 102.7 mg sucrose. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for solution for injection. The powder is a white to off white cake. The solvent is a clear, colourless liquid. The pH of the reconstituted solution is 5.9 – 6.5. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (see section 5.1 – Clinical Efficacy). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with Raptiva should be initiated by a physician specialised in dermatology. An initial single dose of 0.7 mg/kg body weight is given followed by weekly injections of 1.0 mg/kg body weight (maximum single dose should not exceed a total of 200 mg). The volume to be injected should be calculated as follows: Dose Volume to be injected per 10 kg body weight Single initial dose: 0.7 mg/kg 0.07 ml Subsequent doses: 1 mg/kg 0.1 ml The duration of therapy is 12 weeks. Therapy may be continued only in patients who responded to treatment (PGA good or better). For discontinuation guidance Przeczytaj cały dokument